Education
About Us
Working with TipRanks
Follow Us
Hikal Limited (IN:HIKAL)
:HIKAL
HIKAL Stock Chart & Stats
₹227.05
-₹7.35(-1.92%)
At close: 4:00 PM EST
₹227.05
-₹7.35(-1.92%)
Day’s Range― - ―
52-Week Range₹178.00 - ₹456.60
Previous CloseN/A
Volume141.84K
Average Volume (3M)34.88K
Market Cap
₹25.37B
Enterprise Value₹32.07B
Total Cash (Recent Filing)₹340.00M
Total Debt (Recent Filing)₹7.20B
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Jun 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.58%
Share Statistics
EPS (TTM)1.80
Shares Outstanding123,300,750
10 Day Avg. Volume44,586
30 Day Avg. Volume34,881
Financial Highlights & Ratios
PEG Ratio1.79
Price to Book (P/B)3.92
Price to Sales (P/S)2.66
P/FCF Ratio34.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA 55% TTM gross margin indicates durable product-level pricing power from specialty chemistries and differentiated process know-how. High gross margins create a structural buffer to absorb raw-material or energy swings, fund R&D/CDMO investments, and support long-term profitability.
Robust Cash GenerationSizable TTM free cash flow and a 3.09 operating cash flow-to-net-income ratio show strong cash conversion quality. Persistent cash generation supports capex for capacity/R&D, working capital needs, and debt reduction, enabling durable strategic flexibility over months to years.
Balanced Leverage & Improving ROEModerate leverage and roughly 50% equity financing provide balance-sheet resilience and room to fund growth without overextending. An improving 7.2% ROE signals better capital efficiency; together these structural metrics support sustainable investment and withstand industry cyclicality.
Bears Say
Inconsistent Revenue GrowthVolatile top-line trends indicate demand cyclicality across pharma and crop-protection end markets and reliance on project timing. Inconsistent revenue makes capacity planning and margin sustainability harder, limiting visibility for multi-quarter investment and growth execution.
Volatile Free Cash Flow HistoryAlthough current TTM FCF is strong, historical volatility in free cash flow suggests sensitivity to working-capital swings, project receipts and timing. This variability raises execution risk for sustained reinvestment, debt servicing, and long-term cash-backed initiatives.
Negative EPS Growth HistoricallyA large negative historical EPS growth rate signals earnings instability and potential one-offs or margin pressure in prior periods. Restoring consistent EPS expansion is essential to convert improved margins and cash flow into durable shareholder returns and validate operational gains.
Hikal Limited News
HIKAL FAQ
What was Hikal Limited’s price range in the past 12 months?
Hikal Limited lowest stock price was ₹178.00 and its highest was ₹456.60 in the past 12 months.
What is Hikal Limited’s market cap?
Hikal Limited’s market cap is ₹25.37B.
When is Hikal Limited’s upcoming earnings report date?
Hikal Limited’s upcoming earnings report date is Jun 18, 2026 which is in 114 days.
How were Hikal Limited’s earnings last quarter?
Hikal Limited released its earnings results on Feb 11, 2026. The company reported ₹1.8 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.8.
Is Hikal Limited overvalued?
According to Wall Street analysts Hikal Limited’s price is currently Overvalued.
Does Hikal Limited pay dividends?
Hikal Limited pays a Semiannually dividend of ₹0.8 which represents an annual dividend yield of 0.58%. See more information on Hikal Limited dividends here
What is Hikal Limited’s EPS estimate?
Hikal Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikal Limited have?
Hikal Limited has 123,300,750 shares outstanding.
What happened to Hikal Limited’s price movement after its last earnings report?
Hikal Limited reported an EPS of ₹1.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.977%.
Which hedge fund is a major shareholder of Hikal Limited?
Currently, no hedge funds are holding shares in IN:HIKAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal healthcare, biotech, crop protection, and specialty chemicals companies. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs). The Crop Protection segment manufactures pesticides and herbicides. The company collaborates with other companies and offer solutions in contract research, custom synthesis, and custom manufacturing of intermediates and APIs. It also provides specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Technical Analysis
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
RPG Life Sciences Limited
―
―
Unichem Laboratories Limited
―